Rheumazentrum Ruhrgebiet

Befragung zu den Arbeits-, Weiterbildungs- und Forschungsbedingungen von Assistenzärztinnen und -ärzten in der internistisch-rheumatologischen Weiterbildung – BEWUSST (2023) Proft F, Vossen D, Baraliakos X, Berliner MN, Fleck M, Keyßer G, Krause A, et al. Journal article EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis (2023) Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, et al. Journal article Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA. (2023) Regierer AC, Weiß A, Proft F, Baraliakos X, Behrens F, Poddubnyy D, Schett G, et al. Journal article Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial (2023) Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male - Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial (2022) Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Rech J, Burmester G, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL (2022) Koehm M, Rossmanith T, Foldenauer AC, Kellner H, Kiltz U, Rech J, Burmester GR, et al. Conference contribution COMPARISON OF PATIENTS WITH AXIAL PSA AND PATIENTS WITH AXSPA AND CONCOMITANT PSORIASIS (2022) Regierer A, Weiss A, Baraliakos X, Behrens F, Poddubnyy D, Schett G, Lorenz HM, et al. Conference contribution QUANTITATIVE ANALYSIS BY SODIUM AND PROTON BASED 3-TESLA MR IMAGING OF THE ACHILLES TENDON (2022) Muller-Lutz A, Kamp B, Klein-Schmeink L, Tsiami S, Frenken M, Nagel AM, Baraliakos X, Sewerin P Conference contribution